Art. -Nr.: HY-13324

Bardoxolone methyl

(Synonyms: RTA 402; NSC 713200; CDDO Methyl ester)

42 Cited Publications

Kundenbewertung

Based on 42 publication(s) in Google Scholar

Bardoxolone methyl (RTA 402) is an orally active and blood-brain-barrier-penetrant activator of Nrf2 and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone methyl inhibits SARS-CoV-2 replication in Vero cells with an EC₅₀ value of 0.29 μM. Bardoxolone methyl increases levels of pNrf2 and HO-1, inhibits inflammatory mediators like pNFκB and MCP-1. Bardoxolone methyl activates the Nrf2 pathway to enhance antioxidant and anti-inflammatory responses, inhibits viral replication, and improves mitochondrial function. Bardoxolone methyl can be used in research on chemotherapy-induced neuropathic pain (CINP), COVID-19, and chronic kidney disease (CKD).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.66%
CAS. Nr.: 218600-53-4
Formel: C₃₂H₄₃NO₄
Molecular Weight:505.69

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Bardoxolone methyl Chemical Structure

CAS. Nr.: 218600-53-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (42)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Nrf2^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.36 μM Compound: CDDO-Me	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31051401]
A549	IC₅₀	0.52 μM Compound: CDDO-Me	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 31725288]
A549	IC₅₀	0.63 μM Compound: CDDO-Me	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35238566]
A549	IC₅₀	2.074 μM Compound: CDDO-Me	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29501947]
A549/TR	IC₅₀	1.703 μM Compound: CDDO-Me	Antiproliferative activity against human A549/TR cells after 72 hrs by MTT assay Antiproliferative activity against human A549/TR cells after 72 hrs by MTT assay	[PMID: 29501947]
B16-F10	IC₅₀	5.85 μM Compound: CDDO-Me	Cytotoxicity against mouse B16F10 cells after 48 hrs by MTT assay Cytotoxicity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 24685545]
BGC-823	IC₅₀	0.5 μM Compound: CDDO-Me	Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 39091011]
BGC-823	IC₅₀	0.5 μM Compound: CDDO-Me	Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell proliferation preincubated with H2O2 for 2 hrs followed by compound addition and measured after 48 hrs by MTT assay Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell proliferation preincubated with H2O2 for 2 hrs followed by compound addition and measured after 48 hrs by MTT assay	[PMID: 39091011]
CCD-841CoN	IC₅₀	0.316 μM Compound: CDDO-Me	Antiproliferative activity against human CCD-841-CoN cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Antiproliferative activity against human CCD-841-CoN cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 25675144]
GES1	IC₅₀	0.4 μM Compound: CDDO-Me	Cytotoxicity against human GES1 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 39091011]
H9c2	IC₅₀	5.2 μM Compound: CDDO-Me	Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28994286]
HCT-116	IC₅₀	0.25 nM Compound: CDDO-Me	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 30429953]
HCT-116	IC₅₀	0.84 μM Compound: CDDO-Me	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35238566]
HCT-8	IC₅₀	0.29 μM Compound: CDDO-Me	Antiproliferative activity against human HCT8 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT8 cells after 72 hrs by SRB assay	[PMID: 30429953]
HCT-8	IC₅₀	0.363 μM Compound: CDDO-Me	Antiproliferative activity against 5-FU resistant human HCT8 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Antiproliferative activity against 5-FU resistant human HCT8 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 25675144]
HCT-8	IC₅₀	0.399 μM Compound: CDDO-Me	Antiproliferative activity against human HCT8 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 25675144]
HEK293	IC₅₀	2.2 μM Compound: CDDO-Me	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28994286]
HepG2	IC₅₀	0.26 μM Compound: CDDO-Me	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31051401]
HepG2	IC₅₀	0.5 μM Compound: CDDO-Me	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 39091011]
HepG2	IC₅₀	0.52 μM Compound: CDDO-Me	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 31725288]
HepG2	IC₅₀	4.99 μM Compound: CDDO-Me	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24685545]
HOS	IC₅₀	0.66 μM Compound: CDDO-Me	Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 31725288]
HT-29	EC₅₀	4.34 μM Compound: 10; CDDO-Me	Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay	[PMID: 33248849]
HT-29	IC₅₀	0.28 μM Compound: CDDO-Me	Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 30429953]
L02	IC₅₀	0.4 μM Compound: CDDO-Me	Cytotoxicity against human L02 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 39091011]
L929	EC₅₀	>10 μM Compound: 10; CDDO-Me	Anti-necroptotic activity in mouse L929 cells assessed as inhibition of TNFalpha/Z-VAD-fmk (TZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay Anti-necroptotic activity in mouse L929 cells assessed as inhibition of TNFalpha/Z-VAD-fmk (TZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay	[PMID: 33248849]
Macrophage	IC₅₀	0.2 nM Compound: CDDO-Me	Antiinflammatory activity in CD-1 mouse Macrophage assessed as inhibition of IFN-gamma induced NO production after 48 hrs by Griess reaction Antiinflammatory activity in CD-1 mouse Macrophage assessed as inhibition of IFN-gamma induced NO production after 48 hrs by Griess reaction	[PMID: 21361338]
MCF-10A	IC₅₀	0.8 μM Compound: CDDO-Me	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 39091011]
MCF7	IC₅₀	0.05 μM Compound: CDDO-Me (2)	Inhibitory concentration against proliferation of MCF-7 (ER Positive) breast cancer cells Inhibitory concentration against proliferation of MCF-7 (ER Positive) breast cancer cells	[PMID: 15369396]
MCF7	IC₅₀	0.35 μM Compound: CDDO-Me	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31051401]
MCF7	IC₅₀	0.85 μM Compound: CDDO-Me	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 31725288]
MCF7	IC₅₀	1.2 μM Compound: CDDO-Me	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 39091011]
MDA-MB-231	IC₅₀	0.56 μM Compound: CDDO-Me	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35238566]
MGC-803	IC₅₀	0.9 μM Compound: CDDO-Me	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 39091011]
NCI-N87	IC₅₀	0.8 μM Compound: CDDO-Me	Antiproliferative activity against human NCI-N87 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-N87 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 39091011]
RAW264.7	IC₅₀	4 μM Compound: 41; CDDO-Me	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of nitric oxide production Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of nitric oxide production	[PMID: 28754470]
SGC-7901	IC₅₀	0.6 μM Compound: CDDO-Me	Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 39091011]
U2OS	IC₅₀	0.74 μM Compound: CDDO-Me	Antiproliferative activity against human U2OS cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human U2OS cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35238566]

In Vitro

Bardoxolone methyl (5, 10 mg/kg) significantly decreases in levels of renal KIM-1, NGAL, TNF-α, TOS, OSI and improves deterioration in glomeruli and tubules similarly to NAC (HY-B0215) in rat kidney homogenates^[3].
Bardoxolone methyl (0.3 and 1 μM, 28 h) decreases PAC-induced mitochondrial damage in the dorsal root ganglia (DRG) neuronal cell lines and increases pNRf2 intensity in the PAC-treated DRG cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[4]

Cell Line:

PAC (10 µM)-treated DRG Cells
Concentration:

0.3 and 1 μM
Incubation Time:

28 h
Result:

Increased pNRf2 intensity in PAC-treated DRG cells.

In Vivo

Bardoxolone methyl (30 mg/kg, p.o.) decreases renal expression of megalin but not cubilin, increases creatinine clearance and urinary albumin-to-creatinine ratios, and induces Nrf2 cytoprotective targets in cynomolgus monkeys^[1].
Bardoxolone methyl induces overall favorable effects on the heart via its improvement in eGFR in both animal models and clinical trials^[2].
Bardoxolone methyl(5, 10 mg/kg) decreased the percentage of caspase-3 immunopositive cells in a dose-dependent manner in rat kidney ^[3].
Bardoxolone methyl (0-10 mg/kg, i.p., a single dose) results in analgesia but not sedation in rats^[4].
Bardoxolone methyl [10 mg/kg, twice-daily on day 21 after the first PAC (HY-B0015) injection] decreases PAC-induced levels of pNFκB and MCP-1 by increasing pNRf2 and HO-1 in rat DRG^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 218600-53-4
Appearance Solid
Molecular Weight 505.69
Formel C₃₂H₄₃NO₄
Color White to yellow
SMILES

O=C1C(C#N)=C[C@@]2(C)[C@](CC[C@]([C@@]3(C)[C@@]4([H])[C@@]5([H])[C@@](CCC(C)(C)C5)(C(OC)=O)CC3)(C)C2=CC4=O)([H])C1(C)C
Synonyms

RTA 402; NSC 713200; CDDO Methyl ester
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (42)

All RT-PCRFlow CytometryWB

Sort by:

Journal Impact Factor

Nat Commun

Glutathione synthesis in the mouse liver supports lipid abundance through NRF2 repression. [Abstract]

2024 Jul 21;15(1):6152. PMID: 39034312

Bardoxolone methyl purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 21;15(1):6152. [Abstract]

Relative mRNA expression of Scd1 in the liver of WT mice following a 4-day treatment with either vehicle (n = 4) or Bardoxolone methyl (n = 8). Expression levels were normalized to the expression of the reference gene Rps9. An unpaired two-tailed t-test was used to determine statistical significance (Vehicle vs.Bardoxolone methyl P value = 0.0065).

Bardoxolone methyl purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 21;15(1):6152. [Abstract]

Triglyceride levels in the serum of WT mice without AAV-TBG-Cre injection following a 4-day treatment with either vehicle (n = 4) or Bardoxolone methyl (n = 8). An unpaired two-tailed t test was used to determine statistical significance (Vehicle vs. Bardoxolone methyl P value = 0.0171).
Nat Commun

Single-cell RNA-sequencing of herpes simplex virus 1-infected cells connects NRF2 activation to an antiviral program. [Abstract]

2019 Oct 25;10(1):4878. PMID: 31653857

Bardoxolone methyl purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Oct 25;10(1):4878. [Abstract]

HEK 293 cells transfected with the reporter plasmid, and 24 h later treated with DMSO (red) or Bardoxolone methyl (0.4 μM, blue). Ratios of GFP to BFP signal were measured by FACS 15 h later and are displayed as overlapping histograms.

Bardoxolone methyl purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Oct 25;10(1):4878. [Abstract]

HEK 293 cells were infected with the HSV-1 VP26-mCherry virus at an MOI of 1. After removal of virus inoculum and washing with PBS, conditioned medium supplied with solvent or Bardoxolone methyl (0.4 μM) was added.

Bardoxolone methyl purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Oct 25;10(1):4878. [Abstract]

In the primary fibroblasts but not HEK293 cells, the levels of these mRNAs were somewhat reduced, indicating that Bardoxolone methyl (0.1-0.4 μM, 16 h) could also dampen cell cycle progression or promote cell cycle exit.
Chem Eng J

2025 Nov 7;525:170493.
Int J Biol Macromol

Role of ionizing radiation activated NRF2 in lung cancer radioresistance. [Abstract]

2023 Jun 30:241:124476. PMID: 37076059
Biomed Pharmacother

Targeted-lung delivery of bardoxolone methyl using PECAM-1 antibody-conjugated nanostructure lipid carriers for the treatment of lung inflammation. [Abstract]

2024 Aug 5:178:116992. PMID: 39106709
Blood Adv

Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma. [Abstract]

2022 Apr 12;6(7):2346-2360. PMID: 35030628
Antioxidants (Basel)

Effect of Media Composition and Oxygen Tension on Cellular Stress Response and Nrf2 Activation in HepG2ARE Cells. [Abstract]

025 Jan 24;14(2):137. PMID: 40002325
Antioxidants (Basel)

The Effects of Two Nrf2 Activators, Bardoxolone Methyl and Omaveloxolone, on Retinal Ganglion Cell Survival during Ischemic Optic Neuropathy. [Abstract]

2021 Sep 15;10(9):1466. PMID: 34573098
Eur J Med Chem

Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. [Abstract]

2021 Feb 15;212:113030. PMID: 33248849
Kidney Int Rep

Oxidative Stress Contributes to Slit Diaphragm Defects Caused by Disruption of Endocytosis. [Abstract]

2023 Nov 25;9(2):451-463. PMID: 38344712
Drug Deliv Transl Res

Leveraging quantum chemical properties in transfer learning for predicting blood-brain barrier permeability of drugs. [Abstract]

2025 Oct 29. PMID: 41160380
Commun Biol

NRF2 activators and the inhibitor of nuclear export, selinexor, restrict coronaviruses by targeting a network involving ACE2, TMPRSS2, and XPO1 through an NRF2-independent mechanism. [Abstract]

2026 Feb 20. PMID: 41721027
Commun Biol

Spermidine from arginine metabolism activates Nrf2 and inhibits kidney fibrosis. [Abstract]

2023 Jun 28;6(1):676. PMID: 37380734
Front Bioeng Biotechnol

Bardoxolone Methyl Ameliorates Compression-Induced Oxidative Stress Damage of Nucleus Pulposus Cells and Intervertebral Disc Degeneration Ex Vivo. [Abstract]

2022 Feb 1;9:814040. PMID: 35178384
Eur J Pharmacol

Leonurine attenuates cisplatin-induced AKI-CKD transition via Nrf2-Mediated ferroptosis suppression. [Abstract]

2025 Dec 23:1013:178508. PMID: 41448263
Int Immunopharmacol

Nrf2 inhibits M1 macrophage polarization to ameliorate renal ischemia-reperfusion injury through antagonizing NF-κB signaling. [Abstract]

2024 Oct 8;143(Pt 1):113310. PMID: 39383788
Int Immunopharmacol

Bardoxolone methyl breaks the vicious cycle between M1 macrophages and senescent nucleus pulposus cells through the Nrf2/STING/NF-κB pathway. [Abstract]

2024 Jan 25:127:111262. PMID: 38101216
Mol Neurobiol

Bardoxolone Methyl Ameliorates Hyperglycemia Induced Mitochondrial Dysfunction by Activating the keap1-Nrf2-ARE Pathway in Experimental Diabetic Neuropathy. [Abstract]

2020 Aug;57(8):3616-3631. PMID: 32556916
Environ Toxicol Pharmacol

Assessment of the toxicity of acrolein on an alveolus microphysiological system. [Abstract]

2026 Mar:122:104954. PMID: 41644025
J Pharmacol Exp Ther

CDDO-Me Elicits Anti-Breast Cancer Activity by Targeting LRP6 and FZD7 Receptor Complex. [Abstract]

2020 Apr;373(1):149-159. PMID: 32015160
Brain Res Bull

Treadmill exercise attenuates CUMS-induced depressive behaviors by modulating the UPRmt via the Nrf2/Keap1 pathway. [Abstract]

2026 Feb:235:111738. PMID: 41554300
Heliyon

Activation of NRF2 blocks HIV replication and apoptosis in macrophages. [Abstract]

2022 Dec 23;9(1):e12575. PMID: 36691556
J Cell Sci

AKR1B10 negatively regulates autophagy through reducing GAPDH upon glucose starvation in colon cancer. [Abstract]

2021 Apr 15;134(8):jcs255273. PMID: 33758077
Food Chem Toxicol

CDDO-Me triggers ROS-dependent ferroptosis and apoptosis in cervical cancer via targeting PI3K/Nrf2 pathway. [Abstract]

2025 Oct:204:115664. PMID: 40714179
Viruses

Inhibitors of the Ubiquitin-Mediated Signaling Pathway Exhibit Broad-Spectrum Antiviral Activities against New World Alphaviruses. [Abstract]

2023 Feb 28;15(3):655. PMID: 36992362
Food Chem Toxicol

Lonp1 and Sig-1R contribute to the counteraction of ursolic acid against ochratoxin A-induced mitochondrial apoptosis. [Abstract]

2023 Feb:172:113592. PMID: 36587836
ChemMedChem

Andrographolide Derivatives Target the KEAP1/NRF2 Axis and Possess Potent Anti-SARS-CoV-2 Activity. [Abstract]

2022 Mar 4;17(5):e202100732. PMID: 35099120
Cell Transplant

Effects of FGF2 Priming and Nrf2 Activation on the Antioxidant Activity of Several Human Dental Pulp Cell Clones Derived From Distinct Donors, and Therapeutic Effects of Transplantation on Rodents With Spinal Cord Injury. [Abstract]

2024 Jan-Dec:33:9636897241264979. PMID: 39076100
Naunyn Schmiedebergs Arch Pharmacol

A network pharmacology-based study on the mechanism of hirudin attenuates renal interstitial fibrosis through Nrf2 and NF-κB signalling pathways. [Abstract]

2026 Jan 31. PMID: 41617993
Korean J Pain

Pulsed radiofrequency attenuates mechanical hypersensitivity in neuropathic pain rats by activating the Nrf2-regulated CaMKII/NF-κB signaling pathway. [Abstract]

2026 Jan 1;39(1):86-95. PMID: 41469215
Biol Reprod

Bardoxolone methyl modulates Nrf2/NF-𝜅B signaling in turkey uterovaginal junction organoids with potential use for improving reproductive longevity in breeder hens. [Abstract]

2026 Jun 11:ioag122. PMID: 42276551
Toxicol Lett

Bardoxolone methyl modulates efflux transporter and detoxifying enzyme expression in cisplatin-induced kidney cell injury. [Abstract]

2016 Sep 30:259:52-59. PMID: 27480280

Bardoxolone methyl purchased from MedChemExpress. Usage Cited in: Toxicol Lett. 2016 Sep 30:259:52-59. [Abstract]

MATE1/SCL47A1 efflux transporter expression in hPTCs. Protein (n=3) expression is assessed after administration of NSC 119875 and pre- or delayedexposure to CDDO-Me after 12 h. GAPDH is used as a housekeeping gene. β-actin is used as a loading control.
Toxicon

Ameliorative effect of ursolic acid on ochratoxin A-induced renal cytotoxicity mediated by Lonp1/Aco2/Hsp75. [Abstract]

2019 Oct:168:141-146. PMID: 31356822
J Histochem Cytochem

Bardoxolone Methyl Prevents High-Fat Diet-Induced Colon Inflammation in Mice. [Abstract]

2016 Apr;64(4):237-55. PMID: 26920068
Res Sq

2025 Dec 18.
bioRxiv

2025 February 24.
AAPS Open

Bardoxolone methyl improves survival and reduces clinical measures of kidney injury in tumor-bearing mice treated with cisplatin. [Abstract]

2025:11:6. PMID: 40881130
Research Square Preprint

2023 Oct 12.
bioRxiv

2023 Jun 11.
Research Square Preprint

2023 May 5.
Research Square Preprint

2021 Jan.
University of Wollongong

2017 Dec.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (98.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9775 mL

9.8875 mL

19.7750 mL

5 mM

0.3955 mL

1.9775 mL

3.9550 mL

10 mM

0.1977 mL

0.9887 mL

1.9775 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Reisman SA, et al. Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney. J Am Soc Nephrol. 2012 Aug 2. [Content Brief]

[2]. McCullough PA, et al. Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl. Drug Des Devel Ther. 2012;6:141-9. [Content Brief]

[3]. Yasemin Teksen, et al. Bardoxolone methyl attenuates acetaminophen-induced acute kidney injury by suppressing oxidative stress, inflammation and apoptosis[J]. 2024 May 29;31(5):372–379

[4]. Kim HK, et al. Bardoxolone Methyl Ameliorates Chemotherapy-Induced Neuropathic Pain by Activation of Phosphorylated Nuclear Factor Erythroid 2-Related Factor 2 in the Dorsal Root Ganglia. Anesth Analg. 2024 Mar 1;138(3):664-675. [Content Brief]

[5]. Sun Q, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9775 mL	9.8875 mL	19.7750 mL	49.4374 mL
	5 mM	0.3955 mL	1.9775 mL	3.9550 mL	9.8875 mL
	10 mM	0.1977 mL	0.9887 mL	1.9775 mL	4.9437 mL
	15 mM	0.1318 mL	0.6592 mL	1.3183 mL	3.2958 mL
	20 mM	0.0989 mL	0.4944 mL	0.9887 mL	2.4719 mL
	25 mM	0.0791 mL	0.3955 mL	0.7910 mL	1.9775 mL
	30 mM	0.0659 mL	0.3296 mL	0.6592 mL	1.6479 mL
	40 mM	0.0494 mL	0.2472 mL	0.4944 mL	1.2359 mL
	50 mM	0.0395 mL	0.1977 mL	0.3955 mL	0.9887 mL
	60 mM	0.0330 mL	0.1648 mL	0.3296 mL	0.8240 mL
	80 mM	0.0247 mL	0.1236 mL	0.2472 mL	0.6180 mL

Bardoxolone methyl

42 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Bardoxolone methyl

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Rare Diseases Drug Library

EMA-Approved Drug Library

Anti-Pulmonary Fibrosis Compound Library

Chemokine Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Protease Inhibitor Library

Mitochondrial Toxicity Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

High-Throughput Bioactive Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Bardoxolone methyl

Biologische Aktivität

Chemical Information

Publications (42)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bardoxolone methyl Related Classifications

Art. -Nr.: HY-13324